BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Intas, Torrent, Ajanta and AstraZeneca lead growth charge as pharma companies report strong revenue and volume gains in May 2026: Pharmarack

14 June 2026 | News | By Narayan Kulkarni

Intas Pharmaceuticals emerged as one of the strongest performers



The Indian Pharmaceutical Market (IPM) maintained its robust growth momentum in May 2026, recording 10.9 per cent value growth and 1.4 per cent volume growth, with a majority of leading pharmaceutical companies posting healthy gains in both revenue and volumes. Among the top 40 pharmaceutical companies, several players outperformed the market by delivering double-digit growth in both value and volume terms, reflecting strong prescription demand and portfolio performance across therapy areas, according to latest report from Pharmarack Technologies.

Among the Top 20 companies, Intas Pharmaceuticals emerged as one of the strongest performers, reporting monthly sales of Rs 911 crore and registering 19.8 per cent value growth along with 6.4 per cent volume growth. Torrent Pharmaceuticals followed closely with monthly sales of Rs 1,181 crore, delivering 17.8 per cent value growth, the highest among the Top 10 companies, while maintaining stable volumes. Glenmark Pharmaceuticals recorded monthly sales of Rs 482 crore, posting 16.6 per cent value growth and 6.2 per cent volume growth, while USV reported sales of Rs 463 crore with 14.1 per cent value growth and 6.0 per cent volume growth. Ipca Laboratories also delivered a strong performance, generating Rs 427 crore in sales and reporting 14.0 per cent value growth alongside 5.5 per cent volume growth.

Among the industry's largest players, Cipla reported monthly sales of Rs 1,216 crore, recording 12.4 per cent value growth and 10.2 per cent volume growth, while Abbott India posted 10.8 per cent value growth and 10.9 per cent volume growth on sales of Rs 1,292 crore. Sun Pharma, the country's largest pharmaceutical company by sales, registered 11.5 per cent value growth and 3.3 per cent volume growth, with monthly sales of Rs 1,806 crore.

Among companies ranked 21 to 40, AstraZeneca India emerged as the fastest-growing company, recording 22.3 per cent value growth and 11.2 per cent volume growth on monthly sales of Rs 106 crore. Ajanta Pharma followed with 22.2 per cent value growth and 16.2 per cent volume growth, supported by monthly sales of Rs 186 crore. Other notable performers included Corona Remedies, which reported 21.5 per cent value growth and 3.2 per cent volume growth, and La Renon Healthcare, which registered 21.2 per cent value growth along with 7.2 per cent volume growth. Nutricia International posted 16.4 per cent value growth, while Procter & Gamble Health recorded 15.1 per cent value growth and 6.3 per cent volume growth. Several companies also reported exceptional volume expansion. Ajanta Pharma led the pack with 16.2 per cent volume growth, followed by FDC at 13.3 per cent, AstraZeneca India at 11.2 per cent, Abbott India at 10.9 per cent, Cipla at 10.2 per cent, and Sanofi India at 9.4 per cent.

The broad-based growth across leading companies reflects sustained demand across chronic and acute therapies, supported by strong brand performance and expanding patient uptake. Commenting on the market performance, Sheetal Sapale, Vice President – Commercial at Pharmarack Technologies, said "The Indian Pharmaceutical Market continued its healthy growth trajectory in May 2026, with a majority of leading companies reporting positive performance in both value and volume terms. Strong growth among large and mid-sized companies reflects resilient demand across key therapy segments, while double-digit volume growth among several players underscores the strength of underlying prescription demand and market expansion."

Key Growth Leaders in May 2026

- **AstraZeneca India:** 22.3 per cent value growth; 11.2 per cent volume growth
- **Ajanta Pharma:** 22.2 per cent value growth; 16.2 per cent volume growth
- **La Renon Healthcare:** 21.2 per cent value growth; 7.2 per cent volume growth
- **Corona Remedies:** 21.5 per cent value growth; 3.2 per cent volume growth
- **Intas Pharmaceuticals:** 19.8 per cent value growth; 6.4 per cent volume growth
- **Torrent Pharmaceuticals:** 17.8 per cent value growth
- **Glenmark Pharmaceuticals:** 16.6 per cent value growth; 6.2 per cent volume growth
- **Nutricia International:** 16.4 per cent value growth
- **Procter & Gamble Health:** 15.1 per cent value growth; 6.3 per cent volume growth
- **USV:** 14.1 per cent value growth; 6.0 per cent volume growth
- **Ipca Laboratories:** 14.0 per cent value growth; 5.5 per cent volume growth
- **Cipla:** 12.4 per cent value growth; 10.2 per cent volume growth
- **Abbott India:** 10.8 per cent value growth; 10.9 per cent volume growth

Narayan Kulkarni

Narayan.Kulkarni@mmactiv.com